Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition
Individuals with obesity and atherosclerotic cardiovascular disease face an elevated risk of MACE compared with those without obesity, and evolocumab helps to attenuate this risk.
Authors
- Xinhui Ran
- ANTHONY C. KEECH (ORCID: https://orcid.org/0000-0002-9426-9136)
- J. Antonio G. López (ORCID: https://orcid.org/0000-0001-8604-5549)
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Robert P. Giugliano (ORCID: https://orcid.org/0000-0003-4110-7675)
- E. Magnus Ohman
- Maria Laura Monsalvo (ORCID: https://orcid.org/0000-0002-4113-9418)
- Michelle L. O’Donoghue (ORCID: https://orcid.org/0000-0002-8663-0067)
- Sabina A. Murphy (ORCID: https://orcid.org/0000-0002-8231-3611)
- Yu Mi Kang (ORCID: https://orcid.org/0000-0002-6272-0666)
Institutions
- Brigham and Women's Hospital (US)
- The University of Sydney (AU)
- Amgen (United States) (US)
- Thrombolysis in Myocardial Infarction Study Group (US)
- National Health and Medical Research Council (AU)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.jacc.2025.10.036
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00